Disclaimer:

Disclaimer: The blog posts and comments on this blog and posts on social networks are not investment recommendation, are provided solely for informational purposes, and do not constitute an offer or solicitation to buy or sell any securities. The opinions expressed on the blog are Petar Posledovich's. Petar Posledovich does not guarantee the accuracy of the information presented on this blog and social networks. The information presented is "as is". The blog is stocks analysis and valuation, Bitcoin, Cryptocurrencies, Artificial Intelligence, AI, deep-learning focused. Independent, unbiased AI insights. Petar Vladimirov Posledovich is not liable for any investment losses incurred by reading and interpreting blog posts on this blog and posts on social networks. Conflicts of interest: I may possess some of the securities, currencies or their derivatives mentioned in the blog post and posts on social networks! The blog is property of Wolfteam Ltd. www.wolfteamedge.com Respectfully yours, Petar Posledovich

Tuesday, September 19, 2023

Stryker Valuation


Stryker Corp, the American multinational medical technologies corporation is overvalued, according to Wolfteam Ltd.

Stryker Corp with 18.45 billion USD in annual revenue on 12.78 % net profit margin and 7.84 % growth year on year has an estimated intrinsic worth of 92 billion USD, below Stryker Corp's current market capitalization of 111.36 billion USD, according to Wolfteam Ltd.'s projections and estimates.

Stryker Corp's revenue is growing, but not fast enough and Stryker Corp is not very profitable so as to justify its current market capitalization. Stryker Corp's dividend yield of 1.02 % is also not very large a distribution.

Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)